$KRRO

Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19

Korro Bio (KRRO) director Jean Francois Formela reported indirect sales of 28,468 shares of common stock on August 19, 2026, by associated venture funds. The sales, totaling $399K, were made under a Rule 10b5-1 trading plan at a weighted average price of $14.00 per share. Formela disclaims beneficial ownership except for any pecuniary interest.

Original reporting
Published Aug 21, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 7:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$KRRO
Bearish
medium confidence
Mentioned
$KRRO
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$KRROBearishLow
01

Why it matters

The transaction is a routine insider sell with limited material impact; investors should monitor for any larger subsequent disposals.

02

Market read

A small insider sell that may cause a modest, short‑term price dip but carries low trading relevance.

03

What to watch

Potential upcoming financing or dilution events not disclosed; the sale may hint at future capital needs.

Relevance 4/10Novelty 3/10Timing: reported Aug 21, 2026 (sale occurred Aug 19)

Background

Form 4 filing reveals director‑tied venture funds sold shares via a pre‑arranged 10b5‑1 plan, disclosing indirect ownership and sale details.

Company-level read

Ticker impact

$KRROBearishMedium confidence
Context

Director Jean Francois Formela disclosed indirect sale of 28,468 shares at $14 avg via Atlas funds under a Rule 10b5‑1 plan on Aug 19, 2026.

Expected impact

minor short‑term dip, limited to a few cents

Evidence & confidence

Small insider sell under $1M typically signals limited conviction; market impact is expected to be minimal.

Market effects

None; biotech sector not materially affected by a single small insider transaction.

None; impact confined to KRRO shareholders.

None

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals; investors may ignore it.

Key entities

  • Korro Bio, Inc.

    Biotech firm listed on NASDAQ under ticker KRRO.

  • Jean Francois Formela

    Director of Korro Bio, associated with Atlas venture funds.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 — Received Orphan

$NOCMed

Northrop Grumman wins $34.4 million Navy contract modification

Northrop Grumman Systems Corp. received a $34.39 million contract modification from the U.S. Department of War for additional UH-1Y and AH-1Z Helicopter Link-16 Kits and spare parts. The work will be distributed across multiple U.S. locations and is scheduled for completion by March 2027. No funds are obligated at the time of award, with funds to be allocated on individual orders.

$BALowAI 8/10

Boeing vs. Redwire: Which Aerospace Stock Is a Better Buy in 2026?

Boeing (BA) and Redwire (RDW) are compared as aerospace investment options. Boeing, with $89.5B revenue and $2.2B net income in FY 2025, faces operational risks but has strong long-term prospects. Redwire, with $335.4M revenue and a $227M net loss, focuses on space tech and has a conservative debt profile. Both have different risk profiles and valuation metrics.

$MUMed

Micron Investors Get New Reason to Watch Closely

Micron Technology (MU) faces potential strike action in Taiwan as the Taoyuan union demands permanent profit sharing. Negotiations are scheduled for Sept. 18 and 21. A strike could disrupt DRAM and high-bandwidth memory production amid strong AI-driven demand. Micron has offered a one-time bonus but not a permanent profit-sharing system.